Filing Flows › Companies › ANI Pharmaceuticals › Timeline
ANI Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−25.3% to $67.41
ANI Pharmaceuticals (ANIP) stock fell 25% over the last 252 sessions, to $67.41. On the way it reported 5 quarters, its insiders filed 10 open-market trades and 7 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 23.8% | −2.9% (+1.6% vs SPY) | — | — |
| Oct 29, 2026 | Form 144 | Form 144: Stephen Carey plans to sell $613K | +2.0% (+2.4% vs SPY) | −0.1% (+0.6% vs SPY) | — |
| Oct 15, 2026 | Form 144 | Form 144: Nikhil Lalwani plans to sell $379K | +3.0% (+2.7% vs SPY) | +2.9% (+2.5% vs SPY) | — |
| Sep 15, 2026 | Form 144 | Form 144: Nikhil Lalwani plans to sell $380K | +2.4% (+2.9% vs SPY) | +11.3% (+9.4% vs SPY) | +0.6% (−1.9% vs SPY) |
| Sep 11, 2026 | Form 144 | Form 144: Jeanne Thoma plans to sell $71K | −1.8% (−2.6% vs SPY) | +5.4% (+4.7% vs SPY) | +3.4% (+0.4% vs SPY) |
| Aug 25, 2026 | Form 144 | Form 144: Nikhil Lalwani plans to sell $401K | +2.0% (+1.7% vs SPY) | −1.2% (−1.7% vs SPY) | +0.4% (−0.4% vs SPY) |
| Aug 24, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.6% (−1.3% vs SPY) | −3.4% (−3.9% vs SPY) | +3.4% (+2.1% vs SPY) |
| Aug 10, 2026 | Insider sale | Gutwerg Ori sold $243K | −3.2% (−3.2% vs SPY) | −2.2% (−2.6% vs SPY) | −10.8% (−9.9% vs SPY) |
| Aug 7, 2026 | Earnings | Earnings: beat the EPS estimate by 8.2% | −5.4% (−6.1% vs SPY) | −10.0% (−11.2% vs SPY) | −14.8% (−15.1% vs SPY) |
| Jul 29, 2026 | Form 144 | Form 144: Stephen P Carey plans to sell $499K | +0.9% (+2.5% vs SPY) | −2.3% (−6.3% vs SPY) | −8.3% (−11.7% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Patrick Walsh plans to sell $374K | +1.1% (+1.6% vs SPY) | −4.8% (−4.5% vs SPY) | −7.1% (−9.8% vs SPY) |
| May 21, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.1% (−0.4% vs SPY) | −5.3% (−7.1% vs SPY) | +0.2% (+1.2% vs SPY) |
| May 13, 2026 | Insider sale | Walsh Patrick D sold $806K | +1.7% (+1.2% vs SPY) | +1.0% (+1.6% vs SPY) | +2.7% (+2.7% vs SPY) |
| May 12, 2026 | Insider sale | Rowland Thomas Andrew sold $36K | +1.0% (+1.2% vs SPY) | +0.8% (+0.9% vs SPY) | +3.9% (+5.8% vs SPY) |
| May 12, 2026 | Insider sale | Gutwerg Ori sold $220K | +1.0% (+1.2% vs SPY) | +0.8% (+0.9% vs SPY) | +3.9% (+5.8% vs SPY) |
| May 11, 2026 | Insider sale | Walsh Patrick D sold $321K | −3.9% (−4.1% vs SPY) | −4.8% (−5.0% vs SPY) | −0.8% (−0.8% vs SPY) |
| May 11, 2026 | Insider sale | Lalwani Nikhil sold $4.3M | −3.9% (−4.1% vs SPY) | −4.8% (−5.0% vs SPY) | −0.8% (−0.8% vs SPY) |
| May 8, 2026 | Earnings | Earnings: beat the EPS estimate by 57.8% | −2.5% (−3.3% vs SPY) | −5.3% (−7.5% vs SPY) | −4.6% (−5.7% vs SPY) |
| Apr 7, 2026 | 8-K | Change in auditor | −0.6% (−3.1% vs SPY) | −1.5% (−6.7% vs SPY) | +5.6% (−5.1% vs SPY) |
| Mar 11, 2026 | Insider sale | Rowland Thomas Andrew sold $357K | +0.4% (+0.6% vs SPY) | −2.2% (−1.3% vs SPY) | +5.3% (+4.7% vs SPY) |
| Mar 5, 2026 | Insider sale | Carey Stephen P. sold $552K | −1.2% (−0.7% vs SPY) | −0.3% (+1.0% vs SPY) | −3.1% (+1.0% vs SPY) |
| Mar 3, 2026 | Insider sale | Walsh Patrick D sold $445K | +1.2% (+2.1% vs SPY) | −0.6% (+0.6% vs SPY) | +2.2% (+7.3% vs SPY) |
| Mar 3, 2026 | Insider sale | Gutwerg Ori sold $158K | +1.2% (+2.1% vs SPY) | −0.6% (+0.6% vs SPY) | +2.2% (+7.3% vs SPY) |
| Feb 27, 2026 | Earnings | Earnings: beat the EPS estimate by 17.9% | −4.3% (−3.8% vs SPY) | −2.0% (−0.9% vs SPY) | −5.8% (+2.3% vs SPY) |
| Dec 1, 2025 | 8-K | Directors and officers: departures, appointments, pay | −0.4% (0.0% vs SPY) | −3.7% (−4.0% vs SPY) | −6.6% (−7.4% vs SPY) |
| Nov 7, 2025 | Earnings | Earnings: beat the EPS estimate by 15.2% | +0.2% (+0.1% vs SPY) | −6.5% (−6.8% vs SPY) | −10.4% (−12.3% vs SPY) |
Insiders’ record here
In the year on the chart, ANI Pharmaceuticals' insiders reported 0 open-market buys ($0) and 10 sales ($7.4M). Of the 10 old enough to score, 9 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −9.5%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 4.01 Change in auditor | 538 | 0.0% | 49% | −0.1% | ±1.7% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → ANI Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.